Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epigenetic targets in hematopoietic malignancies.

Rainer Claus1, Michael Lübbert

  • 1Department Internal Medicine I, Division Hematology/Oncology, University of Freiburg Medical Center, Hugstetter Str., D-79106 Freiburg, Germany.

Oncogene
|October 7, 2003
PubMed
Summary

Epigenetic alterations like DNA methylation and histone deacetylation silence genes in blood cancers. Therapies targeting these epigenetic changes, such as DNA methyltransferase (Dnmt) and histone deacetylase (HDAC) inhibitors, are being developed for leukemias and lymphomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Blood neoplasia·2026
Same author

Liquid biopsy for early cancer detection in hereditary cancer syndromes: current evidence.

Critical reviews in oncology/hematology·2026
Same author

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies.

International journal of cancer·2026
Same author

Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.

International journal of cancer·2026
Same author

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Blood·2026
Same author

Liquid Biopsy Biomarkers in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Prostate-Specific Membrane Antigen Radioligand Therapy: Protocol for a Prospective, Longitudinal Multicenter Observational Study.

JMIR research protocols·2026

Area of Science:

  • Hematology
  • Epigenetics
  • Oncology

Background:

  • Hematopoietic neoplasias frequently exhibit genetic alterations, but epigenetic modifications also play a crucial role.
  • Gene silencing through DNA methylation and histone deacetylation are key epigenetic mechanisms in these disorders.
  • These epigenetic changes can precede or complement genetic aberrations, impacting tumor suppressor and growth inhibitory genes.

Purpose of the Study:

  • To review the role of epigenetic alterations in hematopoietic neoplasias.
  • To discuss therapeutic strategies for reversing epigenetic silencing in these cancers.
  • To highlight the development and clinical investigation of DNA methyltransferase (Dnmt) and histone deacetylase (HDAC) inhibitors.

Main Methods:

  • Review of existing literature on epigenetic alterations in hematopoietic neoplasias.

Related Experiment Videos

  • Discussion of clinical studies involving Dnmt inhibitors (5-azacytidine, decitabine) and HDAC inhibitors (e.g., sodium phenylbutyrate, valproic acid).
  • Exploration of emerging therapeutic approaches, including antisense molecules and combination therapies.

    • Main Results:

    • DNA methylation and histone deacetylation are significant epigenetic silencing mechanisms in blood cancers.
    • Dnmt inhibitors like 5-azacytidine and decitabine show clinical activity, particularly in myeloid neoplasias.
    • HDAC inhibitors demonstrate promising effects, especially in models like acute promyelocytic leukemia.

    Conclusions:

    • Epigenetic modifications are critical targets for novel therapies in hematopoietic neoplasias.
    • Dnmt and HDAC inhibitors represent promising therapeutic strategies, with ongoing clinical investigations.
    • Combination therapies targeting multiple epigenetic pathways may enhance treatment efficacy and resensitize cancers to biological agents.